Abivax Shares Drop 13% in a Week Despite a 1,283% Surge Over the Year
Abivax stock is significantly down this Tuesday, March 3, dropping 3.61% to 96 euros by midday in a generally declining European market. The French biotech now shows a nearly 13% decrease over the past seven days, following an exceptional annual performance. The upcoming publication of the annual results for 2025, scheduled for March 23, is the next major milestone for the company.
Current Trading Position
The price of Abivax at 96 euros is now significantly below its 50-day moving average of 104.70 euros, indicating a deterioration in short-term momentum. This break occurred after the stock had already breached its 20-day moving average (103.38 euros) in previous sessions, confirming a bearish trend that began in early February. The nearest technical support is at 93.70 euros, a level that could provide stabilization if selling pressure continues. The RSI, at 48, is in a neutral zone, showing no oversold signal, suggesting that the stock has not yet reached an extreme low. Despite this correction, the year-over-year performance remains spectacular, at over 1,283%, reflecting massive revaluation of the stock since 2025.
Upcoming Financial Milestone
The next identified milestone in Abivax's financial calendar is the publication of the 2025 annual results, scheduled for March 23. This event will be closely monitored, as the biopharmaceutical company has experienced a pivotal year in 2025, marked by progress in its clinical pipeline, particularly with obezafimod, its leading molecule targeting chronic inflammatory diseases. The current consolidation of the stock occurs in a context of a general retreat in European markets, affected by geopolitical tensions in the Middle East. The 5.51% decline over three months illustrates a gradual profit-taking movement, following the strong increase throughout 2025. The very low beta of the stock, at 0.01, however, indicates that Abivax's fluctuations remain historically low correlated with overall market movements, with the stock's dynamics primarily driven by clinical and regulatory advancements specific to the company.
